Skip to main content
. 2022 Jul 15;14(14):3452. doi: 10.3390/cancers14143452

Figure 2.

Figure 2

ALK-dependent signalling pathways in EML4-ALK-driven NSCLC. This schematic figure illustrates the three most prominent ALK-dependent signalling pathways activated by EML4-ALK: the MAPK, PI3K/AKT and JAK/STAT signalling pathways. The position at which selected pharmacological inhibitors (trametinib, AZD6244, NVP-BEZ, BKM120, HJC0152) that could act in combination with ALK inhibitors (crizotinib, ceritinib, TAE684) as discussed in the text is indicated. Combinations would work to inhibit activation of these pathways and suppress cancer cell proliferation, survival and migration.